GGrantIndex
Sort

40,608 grants matching prostate cancer

Mechanisms of resistance to treatment in aggressive prostate cancers

$901,721
Adam Sowalsky · Division Of Basic Sciences - Nci · ZIA · FY2023 · CA

Molecular alterations driving the development of primary prostate cancers

$901,721
Adam Sowalsky · Division Of Basic Sciences - Nci · ZIA · FY2023 · CA

Targeted Nanoparticles for Tempospatially Controlled Combination Chemotherapy

$901,531
Robert S Langer · Massachusetts Institute Of Technology · U54 · FY2010 · CA

DISCOVERY AND FUNCTIONAL ANALYSES OF SUSCEPTIBILITY GENES FOR LETHAL PROSTATE CANCER

$900,892
The Johns Hopkins University · · FY2019 · Defense Health Agency

INTEGRATIVE MOLECULAR PROFILING OF WHOLE URINE IN AFRICAN AMERICAN MEN WITH AGGRESSIVE PROSTATE CANCER

$900,875
Regents Of The University Of Michigan · · FY2021 · Defense Health Agency

Exploring Precision Oncology: From Gene Fusions to lncRNAs

$900,791
Arul M Chinnaiyan · University Of Michigan At Ann Arbor · R35 · FY2019 · CA

FUNCTIONAL CHARACTERIZATION OF FORKHEAD-DOMAIN MISSENSE MUTATIONS OF FOXA1 IN DRIVING PROSTATE CANCER PROGRESSION

$900,773
University Of Mass At Boston · · FY2019 · Defense Health Agency

Epigenetics, Stem Cells, and Cancer

$900,709
Rudolf Jaenisch · Whitehead Institute For Biomedical Res · R01 · FY2010 · CA

TARGETING CHROMATIN REMODELING COMPLEXES TO INHIBIT ONCOGENIC ANDROGEN RECEPTOR ACTIVITY IN PROSTATE CANCER.

$900,640
Regents Of The University Of Michigan · · FY2021 · Department of the Army

Development of PSMA -based recombinant protein vaccines

$900,492
Progenics Pharmaceuticals, Inc. · R44 · FY2005 · CA

Role of Neurotrophins in the Development of the Mammalian Nervous System

$900,224
Lino Tessarollo · Division Of Basic Sciences - Nci · ZIA · FY2025 · CA

PSMA GLYCOSYLATION AND AGGRESSIVE PROSTATE CANCER PROGRESSION

$900,000
Old Dominion University · · FY2018 · Department of the Army

Developmental Exposure to Low-dose Bisphenol A and Human Prostate Cancer Suscepti

$899,954
Gail S Prins · University Of Illinois At Chicago · RC2 · FY2009 · ES

Paul Calabresi Program in Clinical-Translational Research at Mayo Clinic

$899,782
Aminah Jatoi · Mayo Clinic Rochester · K12 · FY2014 · CA

The Evaluation of Novel Therapeutics for Genitourinary Malignancies

$899,708
William Laurence Dahut · Division Of Clinical Sciences - Nci · ZIA · FY2018 · CA

Inducing Proximity: An Emerging Paradigm for New Therapeutic Modalities

$898,724
Craig M Crews · Yale University · R35 · FY2023 · CA

DCEG- GWAS Studies

$898,719
Leonard Freedman · Leidos Biomedical Research, Inc. · N01 · FY2024 · CA

STEREOTACTIC BODY RADIATION THERAPY FOR UNDERSERVED POPULATIONS OF MEN WITH LOW AND INTERMEDIATE RISK PROSTATE CANCER

$898,667
The University Of Texas Southwestern Medical Center · · FY2008 · Department of Defense

EXPLOITING REAL-WORLD CLINICAL GENOMIC DATA TO DISCOVER BIOMARKERS AND ADDRESS OUTCOME DISPARITY FOR PROSTATE CANCER

$898,342
Fred Hutchinson Cancer Center · · FY2025 · Defense Health Agency

High throughput infrastructure for reaction screening and bioassays

$898,292
Robert Graham Cooks · Purdue University · UG3 · FY2022 · TR

H. LEE MOFFITT CANCER CENTER CCOP RESEARCH BASE

$898,139
University Of South Florida · U10 · FY2004 · CA

Developmental Exposure to Low-dose Bisphenol A and Human Prostate Cancer Suscepti

$898,116
Gail S Prins · University Of Illinois At Chicago · RC2 · FY2010 · ES

Mayo Clinic Prospective Resource for Biomarker Validation and Early Detection of Pancreatic Cancer

$898,049
Gloria M. Petersen · Mayo Clinic Rochester · U01 · FY2017 · CA

HSP90 and HSP7Chaperone Proteins and Interactors in Cellular Signal Transduction

$897,836
Leonard Neckers · Division Of Clinical Sciences - Nci · ZIA · FY2023 · CA

Paul Calabresi Program in Clinical-Translational Research at Mayo Clinic

$897,597
Aminah Jatoi · Mayo Clinic Rochester · K12 · FY2013 · CA